Welcome to our dedicated page for Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) news (Ticker: CYTO), a resource for investors and traders seeking the latest updates and insights on Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) stock.
Altamira Therapeutics Ltd., formerly known as Auris Medical, is a pioneering company dedicated to developing therapeutics that address significant unmet medical needs. Founded in 2003 and headquartered in Hamilton, Bermuda, with principal operations in Basel, Switzerland, Altamira Therapeutics trades on the NASDAQ Capital Market under the symbol “CYTO”.
Altamira is actively engaged in three primary areas:
- RNA Therapeutics: Utilizing innovative platforms such as OligoPhore™ and SemaPhore™, the company focuses on developing RNA-based therapies targeting extrahepatic sites. These platforms, currently in the preclinical stage, leverage proprietary peptides to form nanoparticles capable of delivering therapeutic RNA to tissues affected by conditions like solid tumors and inflammation.
- Nasal Sprays: The commercially available Bentrio™ nasal spray offers protection against airborne viruses and allergens, while AM-125, which is in Phase 2 clinical trials, targets the treatment of vertigo.
- Inner Ear Disorders: Altamira is progressing with Phase 3 development of Keyzilen® and Sonsuvi® for the intratympanic treatment of tinnitus and hearing loss, respectively.
Altamira Therapeutics is committed to advancing its pipeline through rigorous research and strategic collaborations. Recently, the company has made significant strides with its RNA therapies, as highlighted in studies such as Huang et al. (2021) and Strand et al. (2019), demonstrating the potential of targeting KRAS mutations in cancer. Moreover, ongoing research in peptide-based nanoparticles and NF-κB subunit targeting shows promising applications in inflammatory diseases and cancer treatment.
In the field of nasal sprays, Altamira's Bentrio™ has shown efficacy in clinical trials, with recent studies like Becker et al. (2024) validating its use in protecting against seasonal allergic rhinitis.
Financially, Altamira Therapeutics has reclassified its Bentrio business as discontinued operations, focusing its resources on advancing its core therapeutic areas. The company's investor communications emphasize its forward-looking strategy and commitment to innovation.
Stay updated with the latest news and developments from Altamira Therapeutics by visiting their official website and connecting through their social media channels.
FAQ
What is the current stock price of Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) (CYTO)?
What is the market cap of Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) (CYTO)?
What areas of therapeutics does Altamira Therapeutics focus on?
What are the main products of Altamira Therapeutics?
Where is Altamira Therapeutics headquartered?
What is the stock symbol for Altamira Therapeutics?
What recent achievements has Altamira Therapeutics made in RNA therapeutics?
What stage are the inner ear disorder treatments in?
How does the OligoPhore™ platform work?
What are the recent clinical trial results for Bentrio™?
What is the significance of recent financial reclassifications for Altamira?
How can investors stay updated with Altamira Therapeutics?
